Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic[1] cannabinoid[2] company, focusing on the compound Cannabidiol.[3] The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex,[4] for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.
| Company type | Listed Public Company |
|---|---|
| ASX: BOT | |
| Industry | Biotechnology |
| Headquarters | Perth, Western Australia, and Philadelphia, USA |
Area served | Global |
Key people |
|
| Products | BTX 1503 | For the treatment of moderate to severe acne BTX 1702 | For the treatment of rosaceaBTX 1204A | For the treatment of moderate atopic dermatitis BTX 1801 | For use in a variety of antimicrobial applications |
| Website | www |
Research
Botanix Pharmaceuticals product pipeline[5] currently[when?] includes four programs for treatment of serious skin diseases:
Dermatology
- BTX 1503, for the treatment of moderate to severe acne
- BTX 1702, for the treatment of rosacea
- BTX 1204A, for the treatment of moderate atopic dermatitis
Antimicrobial
- BTX 1801, for use in a variety of antimicrobial applications
